Cargando…

Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals

[Image: see text] With a half-life of 7.45 days, silver-111 (β(max) 1.04 MeV, E(γ) 245.4 keV [I(γ) 1.24%], E(γ) 342.1 keV [I(γ) 6.7%]) is a promising candidate for targeted cancer therapy with β(–) emitters as well as for associated SPECT imaging. For its clinical use, the development of suitable li...

Descripción completa

Detalles Bibliográficos
Autores principales: Tosato, Marianna, Asti, Mattia, Dalla Tiezza, Marco, Orian, Laura, Häussinger, Daniel, Vogel, Raphael, Köster, Ulli, Jensen, Mikael, Andrighetto, Alberto, Pastore, Paolo, Marco, Valerio Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009516/
https://www.ncbi.nlm.nih.gov/pubmed/32658468
http://dx.doi.org/10.1021/acs.inorgchem.0c01405
_version_ 1783672889751371776
author Tosato, Marianna
Asti, Mattia
Dalla Tiezza, Marco
Orian, Laura
Häussinger, Daniel
Vogel, Raphael
Köster, Ulli
Jensen, Mikael
Andrighetto, Alberto
Pastore, Paolo
Marco, Valerio Di
author_facet Tosato, Marianna
Asti, Mattia
Dalla Tiezza, Marco
Orian, Laura
Häussinger, Daniel
Vogel, Raphael
Köster, Ulli
Jensen, Mikael
Andrighetto, Alberto
Pastore, Paolo
Marco, Valerio Di
author_sort Tosato, Marianna
collection PubMed
description [Image: see text] With a half-life of 7.45 days, silver-111 (β(max) 1.04 MeV, E(γ) 245.4 keV [I(γ) 1.24%], E(γ) 342.1 keV [I(γ) 6.7%]) is a promising candidate for targeted cancer therapy with β(–) emitters as well as for associated SPECT imaging. For its clinical use, the development of suitable ligands that form sufficiently stable Ag(+)-complexes in vivo is required. In this work, the following sulfur-containing derivatives of tetraazacyclododecane (cyclen) have been considered as potential chelators for silver-111: 1,4,7,10-tetrakis(2-(methylsulfanyl)ethyl)-1,4,7,10-tetraazacyclododecane (DO4S), (2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetrakis(2-(methylsulfanyl)ethyl)-1,4,7,10-tetraazacyclododecane (DO4S4Me), 1,4,7-tris(2-(methylsulfanyl)ethyl)-1,4,7,10-tetraazacyclododecane (DO3S), 1,4,7-tris(2-(methylsulfanyl)ethyl)-10-acetamido-1,4,7,10-tetraazacyclododecane (DO3SAm), and 1,7-bis(2-(methylsulfanyl)ethyl)-4,10,diacetic acid-1,4,7,10-tetraazacyclododecane (DO2A2S). Natural Ag(+) was used in pH/Ag-potentiometric and UV–vis spectrophotometric studies to determine the metal speciation existing in aqueous NaNO(3) 0.15 M at 25 °C and the equilibrium constants of the complexes, whereas NMR and DFT calculations gave structural insights. Overall results indicated that sulfide pendant arms coordinate Ag(+) allowing the formation of very stable complexes, both at acidic and physiological pH. Furthermore, radiolabeling, stability in saline phosphate buffer, and metal-competition experiments using the two ligands forming the strongest complexes, DO4S and DO4S4Me, were carried out with [(111)Ag]Ag(+) and promising results were obtained.
format Online
Article
Text
id pubmed-8009516
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-80095162021-03-31 Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals Tosato, Marianna Asti, Mattia Dalla Tiezza, Marco Orian, Laura Häussinger, Daniel Vogel, Raphael Köster, Ulli Jensen, Mikael Andrighetto, Alberto Pastore, Paolo Marco, Valerio Di Inorg Chem [Image: see text] With a half-life of 7.45 days, silver-111 (β(max) 1.04 MeV, E(γ) 245.4 keV [I(γ) 1.24%], E(γ) 342.1 keV [I(γ) 6.7%]) is a promising candidate for targeted cancer therapy with β(–) emitters as well as for associated SPECT imaging. For its clinical use, the development of suitable ligands that form sufficiently stable Ag(+)-complexes in vivo is required. In this work, the following sulfur-containing derivatives of tetraazacyclododecane (cyclen) have been considered as potential chelators for silver-111: 1,4,7,10-tetrakis(2-(methylsulfanyl)ethyl)-1,4,7,10-tetraazacyclododecane (DO4S), (2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetrakis(2-(methylsulfanyl)ethyl)-1,4,7,10-tetraazacyclododecane (DO4S4Me), 1,4,7-tris(2-(methylsulfanyl)ethyl)-1,4,7,10-tetraazacyclododecane (DO3S), 1,4,7-tris(2-(methylsulfanyl)ethyl)-10-acetamido-1,4,7,10-tetraazacyclododecane (DO3SAm), and 1,7-bis(2-(methylsulfanyl)ethyl)-4,10,diacetic acid-1,4,7,10-tetraazacyclododecane (DO2A2S). Natural Ag(+) was used in pH/Ag-potentiometric and UV–vis spectrophotometric studies to determine the metal speciation existing in aqueous NaNO(3) 0.15 M at 25 °C and the equilibrium constants of the complexes, whereas NMR and DFT calculations gave structural insights. Overall results indicated that sulfide pendant arms coordinate Ag(+) allowing the formation of very stable complexes, both at acidic and physiological pH. Furthermore, radiolabeling, stability in saline phosphate buffer, and metal-competition experiments using the two ligands forming the strongest complexes, DO4S and DO4S4Me, were carried out with [(111)Ag]Ag(+) and promising results were obtained. American Chemical Society 2020-07-13 2020-08-03 /pmc/articles/PMC8009516/ /pubmed/32658468 http://dx.doi.org/10.1021/acs.inorgchem.0c01405 Text en Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Tosato, Marianna
Asti, Mattia
Dalla Tiezza, Marco
Orian, Laura
Häussinger, Daniel
Vogel, Raphael
Köster, Ulli
Jensen, Mikael
Andrighetto, Alberto
Pastore, Paolo
Marco, Valerio Di
Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals
title Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals
title_full Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals
title_fullStr Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals
title_full_unstemmed Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals
title_short Highly Stable Silver(I) Complexes with Cyclen-Based Ligands Bearing Sulfide Arms: A Step Toward Silver-111 Labeled Radiopharmaceuticals
title_sort highly stable silver(i) complexes with cyclen-based ligands bearing sulfide arms: a step toward silver-111 labeled radiopharmaceuticals
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009516/
https://www.ncbi.nlm.nih.gov/pubmed/32658468
http://dx.doi.org/10.1021/acs.inorgchem.0c01405
work_keys_str_mv AT tosatomarianna highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT astimattia highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT dallatiezzamarco highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT orianlaura highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT haussingerdaniel highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT vogelraphael highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT kosterulli highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT jensenmikael highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT andrighettoalberto highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT pastorepaolo highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals
AT marcovaleriodi highlystablesilvericomplexeswithcyclenbasedligandsbearingsulfidearmsasteptowardsilver111labeledradiopharmaceuticals